Northwest Biotherapeutics, Inc. Share Price Other OTC
Equities
NWBO
US66737P6007
Biotechnology & Medical Research
Sales 2022 | 1.68M 133M | Sales 2023 | 1.93M 152M | Capitalization | 822M 64.71B |
---|---|---|---|---|---|
Net income 2022 | -105M -8.27B | Net income 2023 | -62M -4.88B | EV / Sales 2022 | 505 x |
Net Debt 2022 | 19.29M 1.52B | Net Debt 2023 | 43.43M 3.42B | EV / Sales 2023 | 448 x |
P/E ratio 2022 |
-7.59
x | P/E ratio 2023 |
-11.7
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 90.82% |
Managers | Title | Age | Since |
---|---|---|---|
Linda F. Powers
CEO | Chief Executive Officer | 68 | 16/05/07 |
Alton L. Boynton
FOU | Founder | 79 | 17/03/96 |
Marnix L. Bosch
CTO | Chief Tech/Sci/R&D Officer | 65 | 31/12/99 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alton L. Boynton
FOU | Founder | 79 | 17/03/96 |
Linda F. Powers
CEO | Chief Executive Officer | 68 | 16/05/07 |
Navid Malik
BRD | Director/Board Member | 55 | 31/03/12 |
1st Jan change | Capi. | |
---|---|---|
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |